Natera (NTRA) Enrolls First Patient in SIGNAL-ER 101 Study for Breast Cancer Test

Natera Inc. (NASDAQ: NTRA) enrolled the first patient on May 28, 2026, in its SIGNAL-ER 101 clinical trial, which will evaluate the company’s Signatera circulating tumor DNA test in patients with early-stage breast cancer. The study is designed to assess whether Signatera can detect minimal residual disease after surgery, potentially guiding adjuvant therapy decisions. The trial will enroll participants across multiple sites in the United States. Signatera is already used to monitor multiple tumor types, and a successful expansion into breast cancer would open a substantial new market for Natera. The company has not disclosed the expected enrollment completion date but stated that initial data could provide evidence for broader clinical adoption.